Although the co-occurrence of NRAS mutations and AML1/ETO expression remains elusive, all of these reports suggest that KIT mutants play important roles in CBF leukemia, with negative impacts on the clinical course [65,66,68,69]. The gene discussed is RUNX1T1; the disease is leukemia.